Information Provided By:
Fly News Breaks for June 30, 2015
BCRX
Jun 30, 2015 | 08:45 EDT
As previously reported, BofA/Merrill upgraded BioCryst to Buy from Neutral and increased its price target to $19 from $12. The firm raised the probability of BCX7353 approval to 40% from 25% given validation of the plasma kallikrein target by both ‘4161 and competitor product and now assign a $13/share value versus near zero previously. BofA/Merrill is now assigning a modest negative value for '4161 versus approximately $7/share previously.
News For BCRX From the Last 2 Days
There are no results for your query BCRX